Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
Portfolio Pulse from Vandana Singh
Repare Therapeutics Inc (RPTX) announced the termination of its collaboration with Roche Holdings AG (RHHBY) for the development and commercialization of camonsertib (RP-3500), effective May 7, 2024. This decision follows a review of Roche's pipeline and external factors. Repare will regain global rights to camonsertib, which is part of the ongoing Phase 1 MYTHIC trial. Despite this, Repare has received a $40 million milestone payment from Roche and expects its funds to last into mid-2026. This is Roche's second termination within a month, having previously ended a pact with HOOKIPA Pharma Inc (HOOK) for the HB-700 program.
February 13, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HOOKIPA Pharma regains full control of the HB-700 program in KRAS mutated cancers after Roche terminates the collaboration agreement.
Roche's termination of the collaboration with HOOKIPA Pharma for the HB-700 program is part of its strategic adjustments. The impact on HOOK's stock price in the short term is uncertain, as the company regains full control of the program.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Roche terminates its second collaboration within a month, this time with Repare Therapeutics for camonsertib, following a strategic review.
Roche's decision to terminate the collaboration with Repare Therapeutics is part of a strategic review of its pipeline. This move might not significantly impact Roche's stock in the short term due to its large portfolio and strategic realignment.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Repare Therapeutics regains rights to camonsertib after Roche terminates collaboration. Despite a recent $40 million milestone payment from Roche, RPTX shares dropped 10.8% premarket.
The termination of the collaboration with Roche, a major pharmaceutical company, could be seen negatively by investors, leading to a short-term decrease in RPTX's stock price. However, the $40 million milestone payment and sufficient funds till mid-2026 provide some financial stability.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100